ADC THERAPEUTICS SA (ADCT) 4.63 -0.27 (-5.51%)
4.63 -0.27 (-5.51%)
CH0499880968 - Common Stock
ADC THERAPEUTICS SA4.63
NYSE:ADCT (2/3/2023, 7:23:25 PM)-0.27 (-5.51%)
| GICS Sector | Health Care | ||
| GICS Industry | Biotechnology | ||
| Valuation | Growth | ||
| Profitability | Health | ||
| Dividend | |||
| Earnings (Last) | 11-08 2022-11-08/bmo | Earnings (Next) | N/A N/A |
| Ins Owners | N/A | Inst Owners | 49.6% |
| Market Cap | 356.10M | Shares | 76.91M |
| PE | N/A | Fwd PE | N/A |
| Dividend Yield | N/A | Analysts | 77.14 |
| IPO | 05-15 2020-05-15 | ||
Stock Screener Links
New York Stock Exchange, Inc. Stock Screener
Find more stocks on New York Stock Exchange, Inc.
USA Stock Screener
Find more stocks on the USA
GICS Sector Stock Screener
Find competitors from the same sector on the USA
GICS Industry Stock Screener
Find competitors from the same industry on the USA
Technical Stock Screener
Find stocks with similar TA and Setup ratings on the USA
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Growth Stock Screener
Find more growth stocks the USA
Best Technical Competitors Stock Screener
Find the competitors with the best technical ratings on the USA
Best Technical Setups Competitors Stock Screener
Find the competitors with the best technical and setup ratings on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA
Company Profile
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Company Info
ADC THERAPEUTICS SA
Biopole, route de la Corniche 3B
Epalinges VAUD 1066
P: 41216530200.0
CEO: Christopher Martin
Employees: 312
Website: https://adctherapeutics.com/
ADCT News
3 days ago - Seeking AlphaADC Therapeutics stock slips after pricing stock offering by seller (NYSE:ADCT)ADC Therapeutics (ADCT) shares fell over 6% premarket on Thursday after the biotechnology company announced pricing of an underwritten offering of 12M common shares by A.T
3 days ago - ADC Therapeutics SAADC Therapeutics Announces Pricing of Underwritten Offering by a Selling Shareholder
4 days ago - ADC Therapeutics SAADC Therapeutics to Participate in February Investor Conferencesa month ago - Seeking AlphaIntoCell enters development and license option agreement with ADC Therapeutics (NYSE:ADCT)IntoCell signed a Material Transfer Agreement (or MTA) with option to license with ADC Therapeutics SA (ADCT).Under the agreement, IntoCell, a South Korean biotech developing novel...
a month ago - PharmaVenturesPharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics/PRNewswire/ -- PharmaVentures is pleased to announce that it acted as exclusive advisor for IntoCell on its agreement with ADC Therapeutics (NYSE: ADCT)....
a month ago - IntoCellIntoCell Enters into Development and License Option Agreement with ADC Therapeutics/PRNewswire/ -- IntoCell today announced the signing of a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics SA (NYSE: ADCT). Under...
ADCT Twits
Here you can normally see the latest stock twits on ADCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
